Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data

Video

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Recent Videos
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content